GALT
Galectin Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.65
+6.83%Margins
Gross margin
—
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
20.3%
Return on equity
-187.8%
Return on assets
-1837.9%
Return on invested capital
0.00x
Asset turnover
-$15.9M
Cash from operations
$0.13
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026